BCM
PRVB

BlueCrest Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

BlueCrest Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,294
Closed -$45K – 1535
2018
Q3 		$45K Buy
+11,294
New +$44.6K ﹤0.01% 1447

Other funds holding PRVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlueCrest Capital Management's PRVB Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2018, closing a stake of 11,294 shares — an estimated $45K sold.

BlueCrest Capital Management first reported a position in PRVB in Q3 2018 and held it in 1 quarter. The position peaked at $45K in Q3 2018. 11 funds tracked by Wall St. Rank hold PRVB as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,294 Provention Bio, Inc. Common Stock shares in Q4 2018, an estimated $45K.
  • BlueCrest Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • BlueCrest Capital Management's Provention Bio, Inc. Common Stock position peaked at $45K in Q3 2018.
  • 11 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.